{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:39:12Z","timestamp":1793817552921,"version":"4.6.1"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1097\/pas.0000000000000525","type":"journal-article","created":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T11:34:06Z","timestamp":1443699246000},"page":"1653-1660","source":"Crossref","is-referenced-by-count":102,"title":["Idelalisib-associated Enterocolitis"],"prefix":"10.1097","volume":"39","author":[{"given":"Christine Y.","family":"Louie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"DiMaio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen E.","family":"Matsukuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven E.","family":"Coutre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald J.","family":"Berry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teri A.","family":"Longacre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-7-20210131","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1182\/blood-2010-03-275305","article-title":". CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability.","volume":"117","author":"Lannutti","year":"2011","journal-title":"Blood"},{"key":"R2-7-20210131","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1182\/blood-2010-02-271171","article-title":". Phosphatidylinositol 3-kinase- inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.","volume":"116","author":"Herman","year":"2010","journal-title":"Blood"},{"key":"R3-7-20210131","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1182\/blood-2013-11-535047","article-title":". Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110, for relapsedrefractory chronic lymphocytic leukemia.","volume":"123","author":"Brown","year":"2014","journal-title":"Blood"},{"key":"R4-7-20210131","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":". PI3K inhibition by idelalisib in patients with relapsed indolent lymphoma.","volume":"370","author":"Gopal","year":"2014","journal-title":"N Engl J Med"},{"key":"R5-7-20210131","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":". Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.","volume":"370","author":"Furman","year":"2014","journal-title":"N Engl J Med"},{"key":"R6-7-20210131","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1182\/blood-2013-11-538546","article-title":". Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-, as therapy for previously treated indolent non-Hodgkin lymphoma.","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"key":"R7-7-20210131","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1182\/blood-2013-11-537555","article-title":". A phase 1 study of the PI3K inhibitor idelalisib in patients with relapsedrefractory mantle cell lymphoma (MCL).","volume":"123","author":"Kahl","year":"2014","journal-title":"Blood"},{"key":"R9-7-20210131","first-page":"198A","article-title":". Idelalisib is a novel biologic agent that can cause severe gastrointestinal toxicity (United States and Canadian Acadamy of Pathology Meeting, Abstract 786).","volume":"28","author":"Weidner","year":"2015","journal-title":"Mod Pathol"},{"issue":"suppl 1","key":"R10-7-20210131","doi-asserted-by":"crossref","first-page":"S186","DOI":"10.1093\/ecco-jcc\/jju027.340","article-title":". Idelalisib-induced acute proctocolitis: clinical and histological findings. Abstract P223.","volume":"9","author":"Hendy","year":"2015","journal-title":"J Crohns Colitis"},{"key":"R11-7-20210131","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1097\/PAS.0b013e31816bf3fe","article-title":"Mycophenolate mofetil-related gastrointestinal mucosal injury: variable injury patterns, including graft-versus-host disease-like changes.","volume":"32","author":"Parfitt","year":"2008","journal-title":"Am J Surg Pathol"},{"key":"R12-7-20210131","doi-asserted-by":"crossref","first-page":"e243","DOI":"10.1542\/peds.2009-3395","article-title":". Severe ulcerative colitis after rituximab therapy.","volume":"126","author":"Ardelean","year":"2010","journal-title":"Pediatrics"},{"key":"R13-7-20210131","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1002\/ibd.20215","article-title":". Exacerbation of ulcerative colitis after rituximab salvage therapy.","volume":"13","author":"Goetz","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"R14-7-20210131","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1136\/gut.2007.138305","article-title":". Ulcerative colitis following B lymphocyte depletion with rituximab in a patient with Graves disease.","volume":"57","author":"El Fassi","year":"2008","journal-title":"Gut"},{"key":"R16-7-20210131","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1073\/pnas.0409449102","article-title":". Mesenteric B cells centrally inhibit CD4 T cell colitis through interaction with regulatory T cell subsets.","volume":"102","author":"Wei","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"R17-7-20210131","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/PAS.0b013e31817150e3","article-title":". Alpha-CTLA-4 mAb-associated panenteritis: a histologic and immunohistochemical analysis.","volume":"32","author":"Oble","year":"2008","journal-title":"Am J Surg Pathol"},{"key":"R19-7-20210131","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1002\/cncr.21854","article-title":". Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma.","volume":"106","author":"Reuben","year":"2006","journal-title":"Cancer"},{"issue":"suppl 3","key":"R20-7-20210131","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1365-2133.2007.07856.x","article-title":". The role of apoptosis in therapy and prophylaxis of epithelial tumours by nonsteroidal anti-inflammatory drugs (NSAIDs).","volume":"156","author":"Fecker","year":"2007","journal-title":"Br J Dermatol"},{"key":"R21-7-20210131","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1007\/s00018-008-7511-x","article-title":"NSAIDs and apoptosis.","volume":"65","author":"Jana","year":"2008","journal-title":"Cell Mol Life Sci CMLS"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/PAS.0000000000000525","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:58:58Z","timestamp":1786035538000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00000478-201512000-00007"}},"subtitle":["Clinicopathologic Features and Distinction From Other Enterocolitides"],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":18,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000000525","relation":{},"ISSN":["0147-5185"],"issn-type":[{"value":"0147-5185","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]}}}